Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Note Receivable
Apontis Pharma AG
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
Apontis Pharma AG
XETRA:APPH
|
Note Receivable
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
ATAI Life Sciences NV
NASDAQ:ATAI
|
Note Receivable
$11.3m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Bayer AG
XETRA:BAYN
|
Note Receivable
€1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
13%
|
|
![]() |
Merck KGaA
XETRA:MRK
|
Note Receivable
€36m
|
CAGR 3-Years
1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
![]() |
Dermapharm Holding SE
XETRA:DMP
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
PharmaSGP Holding SE
XETRA:PSG
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Note Receivable?
Note Receivable
0
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Note Receivable amounts to 0 EUR.